OBJECTIVE: To investigate the signaling pathways involved in insulin-like growth factor-1 (IGF-1)-induced vascular endothelial growth factor C (VEGF-C) up-regulation and lymphatic metastasis in MDA-MB-231 breast cancer cells. METHODS: MDA-MB-231 breast cancer cells were exposed to IGF-1 with various concentrations. The expression level of VEGF-C was assessed by real-time PCR and Western blot. Akt and ERK1/2 phosphorylation was detected by Western blot. Signaling transduction inhibitors, LY294002 and PD98059, were used to block PI3K/Akt and MAPK/ERK1/2 signaling pathways, respectively. RESULTS: IGF-1 increased the level of VEGF-C expression in a dose-dependent manner in MDA-MB-231 breast cancer cells. In addition, phosphorylation of Akt and ERK1/2 was enhanced by IGF-1. Remarkably, inhibition of Akt phosphorylation by LY294002 completely blocked the effects on IGF-1-induced VEGF-C up-regulation. Inhibition of ERK1/2 phosphorylation by PD98059 reduced IGF-1-induced VEGF-C expression. CONCLUSION: This study identified that PI3K/Akt and MAPK/ERK1/2 signaling pathways were involved in IGF-1-induced VEGF-C up-regulation and suggested their important roles in lymphatic metastasis in breast cancer.
OBJECTIVE: To investigate the signaling pathways involved in insulin-like growth factor-1 (IGF-1)-induced vascular endothelial growth factor C (VEGF-C) up-regulation and lymphatic metastasis in MDA-MB-231 breast cancer cells. METHODS: MDA-MB-231 breast cancer cells were exposed to IGF-1 with various concentrations. The expression level of VEGF-C was assessed by real-time PCR and Western blot. Akt and ERK1/2 phosphorylation was detected by Western blot. Signaling transduction inhibitors, LY294002 and PD98059, were used to block PI3K/Akt and MAPK/ERK1/2 signaling pathways, respectively. RESULTS:IGF-1 increased the level of VEGF-C expression in a dose-dependent manner in MDA-MB-231 breast cancer cells. In addition, phosphorylation of Akt and ERK1/2 was enhanced by IGF-1. Remarkably, inhibition of Akt phosphorylation by LY294002 completely blocked the effects on IGF-1-induced VEGF-C up-regulation. Inhibition of ERK1/2 phosphorylation by PD98059 reduced IGF-1-induced VEGF-C expression. CONCLUSION: This study identified that PI3K/Akt and MAPK/ERK1/2 signaling pathways were involved in IGF-1-induced VEGF-C up-regulation and suggested their important roles in lymphatic metastasis in breast cancer.
Authors: Steven A Stacker; Rae H Farnsworth; Tara Karnezis; Ramin Shayan; Darrin P Smith; Karri Paavonen; Natalia Davydova; Carol Caesar; Rachael Inder; Megan E Baldwin; Bradley K McColl; Sally Roufail; Richard A Williams; Richard A Hughes; Kari Alitalo; Marc G Achen Journal: Novartis Found Symp Date: 2007
Authors: Tohru Hoshida; Naohide Isaka; Jeroen Hagendoorn; Emmanuelle di Tomaso; Yen-Lin Chen; Bronislaw Pytowski; Dai Fukumura; Timothy P Padera; Rakesh K Jain Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: M Skobe; T Hawighorst; D G Jackson; R Prevo; L Janes; P Velasco; L Riccardi; K Alitalo; K Claffey; M Detmar Journal: Nat Med Date: 2001-02 Impact factor: 53.440
Authors: B Enholm; T Karpanen; M Jeltsch; H Kubo; F Stenback; R Prevo; D G Jackson; S Yla-Herttuala; K Alitalo Journal: Circ Res Date: 2001-03-30 Impact factor: 17.367
Authors: T N Pathiraja; K N Thakkar; S Jiang; S Stratton; Z Liu; M Gagea; X Shi; P K Shah; L Phan; M-H Lee; J Andersen; M Stampfer; M C Barton Journal: Oncogene Date: 2014-07-28 Impact factor: 9.867
Authors: Melanie C Langheinrich; Vera Schellerer; Aristotelis Perrakis; Clemens Lohmüller; Claus Schildberg; Elisabeth Naschberger; Michael Stürzl; Werner Hohenberger; Roland S Croner Journal: Int J Clin Exp Pathol Date: 2012-09-05